Compare Piramal Healthcare with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs NATCO PHARMA - Comparison Results

PIRAMAL ENTERPRISES     Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES NATCO PHARMA PIRAMAL ENTERPRISES/
NATCO PHARMA
 
P/E (TTM) x -31.8 33.2 - View Chart
P/BV x 1.1 5.0 22.1% View Chart
Dividend Yield % 2.1 0.7 310.4%  

Financials

 PIRAMAL ENTERPRISES   NATCO PHARMA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-19
NATCO PHARMA
Mar-19
PIRAMAL ENTERPRISES/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs3,303849 389.0%   
Low Rs1,797557 322.6%   
Sales per share (Unadj.) Rs716.5573.8 124.9%  
Earnings per share (Unadj.) Rs79.7176.0 45.3%  
Cash flow per share (Unadj.) Rs107.9198.2 54.4%  
Dividends per share (Unadj.) Rs28.006.25 448.0%  
Dividend yield (eoy) %1.10.9 123.5%  
Book value per share (Unadj.) Rs1,477.5842.7 175.3%  
Shares outstanding (eoy) m184.4536.50 505.3%   
Bonus/Rights/Conversions ISBB-  
Price / Sales ratio x3.61.2 290.5%   
Avg P/E ratio x32.04.0 800.9%  
P/CF ratio (eoy) x23.63.5 666.2%  
Price / Book Value ratio x1.70.8 206.9%  
Dividend payout %35.13.6 989.3%   
Avg Mkt Cap Rs m470,29225,660 1,832.8%   
No. of employees `0007.85.0 157.8%   
Total wages/salary Rs m22,5043,559 632.3%   
Avg. sales/employee Rs Th16,899.44,225.3 400.0%   
Avg. wages/employee Rs Th2,877.7718.0 400.8%   
Avg. net profit/employee Rs Th1,879.91,295.9 145.1%   
INCOME DATA
Net Sales Rs m132,15320,945 631.0%  
Other income Rs m3,1281,302 240.2%   
Total revenues Rs m135,28122,247 608.1%   
Gross profit Rs m66,2907,948 834.0%  
Depreciation Rs m5,202810 642.2%   
Interest Rs m44,097193 22,848.4%   
Profit before tax Rs m20,1198,247 244.0%   
Minority Interest Rs m3,1940-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,6111,823 472.4%   
Profit after tax Rs m14,7016,424 228.8%  
Gross profit margin %50.237.9 132.2%  
Effective tax rate %42.822.1 193.6%   
Net profit margin %11.130.7 36.3%  
BALANCE SHEET DATA
Current assets Rs m122,74223,472 522.9%   
Current liabilities Rs m310,8107,287 4,265.3%   
Net working cap to sales %-142.377.3 -184.2%  
Current ratio x0.43.2 12.3%  
Inventory Days Days2392 25.0%  
Debtors Days Days3988 44.0%  
Net fixed assets Rs m116,90418,648 626.9%   
Share capital Rs m369365 101.1%   
"Free" reserves Rs m272,16134,525 788.3%   
Net worth Rs m272,53030,760 886.0%   
Long term debt Rs m270,1960-   
Total assets Rs m856,26143,031 1,989.9%  
Interest coverage x1.543.7 3.3%   
Debt to equity ratio x1.00-  
Sales to assets ratio x0.20.5 31.7%   
Return on assets %6.915.4 44.7%  
Return on equity %5.420.9 25.8%  
Return on capital %12.427.4 45.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,20011,536 131.8%   
Fx outflow Rs m4,8892,939 166.3%   
Net fx Rs m10,3128,597 119.9%   
CASH FLOW
From Operations Rs m-115,9756,688 -1,734.1%  
From Investments Rs m-8,265-6,122 135.0%  
From Financial Activity Rs m107,525-509 -21,124.7%  
Net Cashflow Rs m-16,65066 -25,227.6%  

Share Holding

Indian Promoters % 52.9 52.0 101.7%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 4.0 7.8 51.0%  
FIIs % 26.6 16.6 160.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 26.0 63.5%  
Shareholders   93,274 25,395 367.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   GLENMARK PHARMA  FULFORD INDIA  ORCHID PHARMA  AJANTA PHARMA  UNICHEM LAB  

Compare PIRAMAL ENTERPRISES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

SGX Nifty Down 25 Points, Factors Behind the Stock Market Rally, HDFC Bank Q2 Results, and Top Buzzing Stocks Today(Pre-Open)

Indian share markets ended on a strong note yesterday. At the closing bell yesterday, the BSE Sensex stood higher by 448 points (up 1.1%).

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY21); Net Profit Up 22.1% (Quarterly Result Update)

Aug 25, 2020 | Updated on Aug 25, 2020

For the quarter ended June 2020, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 22.1% YoY). Sales on the other hand came in at Rs 29 bn (down 16.2% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY20); Net Profit Up 11.7% (Quarterly Result Update)

Feb 5, 2020 | Updated on Feb 5, 2020

For the quarter ended December 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 11.7% YoY). Sales on the other hand came in at Rs 38 bn (up 9.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY20); Net Profit Up 16.5% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 16.5% YoY). Sales on the other hand came in at Rs 36 bn (up 14.6% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

My Latest Stock Recommendation(Fast Profits Daily)

Oct 9, 2020

How I picked an exciting stock using trends from both the commodity and equity markets.

The 'Seedhi Baat, No Bakwaas' View on ITC(Profit Hunter)

Oct 12, 2020

Is ITC an investment or a speculation at current levels?

How to Shortlist the Best Stocks for Trading(Fast Profits Daily)

Oct 7, 2020

In this video, I'll show you how to identify a confluence of factors in the market which will point you to the best stocks to trade.

The Inflection Point for Defence Stocks is Getting Closer(Profit Hunter)

Oct 9, 2020

Few Indian defence companies could use their engineering capabilities to eventually become global leaders.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Oct 19, 2020 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES - WOCKHARDT COMPARISON

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS